Role of omega-3 fatty acids in the treatment of depressive disorders: a comprehensive meta-analysis of randomized clinical trials
Grosso G, Pajak A, Marventano S, Castellano S, Galvano F, Bucolo C, Drago F, Caraci F
PloS one · 313 citas
Cómo se estudió
- Diseño
- Metaanálisis (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Marcadores de salud y funcionamiento
Quién lo pagó
- Financiación
- Financiación independiente
Según la declaración de financiación del texto completo.
Publicación
- Publicado
- 2014-05-07 · PLoS One · vol. 9 · número 5 · pág. e96905
- Editorial
- Public Library of Science
- Citado
- 448 citas · más que el 98% de estudios similares · 7.2× el promedio de su campo
- Impacto
- Entre el 10 % más citado de su campo
- Referencias
- 131 trabajos
- Acceso
- Acceso abierto (revista) · CC-BY
- Áreas de investigación
- Fatty Acid Research and Health · Treatment of Major Depression · Tryptophan and brain disorders
- Palabras clave
- omega-3 fatty acids, polyunsaturated fatty acids, depression, major depressive disorder, eicosapentaenoic acid, docosahexaenoic acid, omega-3 supplementation, adjuvant therapy, bipolar disorder, perinatal depression, young adults, depression severity
- MeSH
- humans, fatty acids, omega-3, docosahexaenoic acids, eicosapentaenoic acid, depressive disorder, pregnancy, dietary supplements, medline, female, randomized controlled trials as topic
8 autores
- Giuseppe Grosso🇮🇹 · autor de correspondenciaUniversity of Catania
- Andrzej Pająk🇵🇱Jagiellonian University
- Stefano Marventano🇮🇹University of Catania
- Sabrina Castellano🇮🇹University of Catania
- Fabio Galvano🇮🇹University of Catania
- Claudio Bucolo🇮🇹University of Catania
- Filippo Drago🇮🇹University of Catania
- Filippo Caraci🇮🇹University of Catania; Oasi Maria SS; I.R.C.C.S. Oasi Maria SS
Resumen
El texto original del estudio, en el idioma en que se publicó.
Background
Despite omega-3 polyunsaturated fatty acids (PUFA) supplementation in depressed patients have been suggested to improve depressive symptomatology, previous findings are not univocal.
Objectives
To conduct an updated meta-analysis of randomized controlled trials (RCTs) of omega-3 PUFA treatment of depressive disorders, taking into account the clinical differences among patients included in the studies.
Methods
A search on MEDLINE, EMBASE, PsycInfo, and the Cochrane Database of RCTs using omega-3 PUFA on patients with depressive symptoms published up to August 2013 was performed. Standardized mean difference in clinical measure of depression severity was primary outcome. Type of omega-3 used (particularly eicosapentaenoic acid [EPA] and docosahexaenoic acid [DHA]) and omega-3 as mono- or adjuvant therapy was also examined. Meta-regression analyses assessed the effects of study size, baseline depression severity, trial duration, dose of omega-3, and age of patients.
Results
Meta-analysis of 11 and 8 trials conducted respectively on patients with a DSM-defined diagnosis of major depressive disorder (MDD) and patients with depressive symptomatology but no diagnosis of MDD demonstrated significant clinical benefit of omega-3 PUFA treatment compared to placebo (standardized difference in random-effects model 0.56 SD [95% CI: 0.20, 0.92] and 0.22 SD [95% CI: 0.01, 0.43], respectively; pooled analysis was 0.38 SD [95% CI: 0.18, 0.59]). Use of mainly EPA within the preparation, rather than DHA, influenced final clinical efficacy. Significant clinical efficacy had the use of omega-3 PUFA as adjuvant rather than mono-therapy. No relation between efficacy and study size, baseline depression severity, trial duration, age of patients, and study quality was found. Omega-3 PUFA resulted effective in RCTs on patients with bipolar disorder, whereas no evidence was found for those exploring their efficacy on depressive symptoms in young populations, perinatal depression, primary disease other than depression and healthy subjects.
Conclusions
The use of omega-3 PUFA is effective in patients with diagnosis of MDD and on depressive patients without diagnosis of MDD.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial (CC BY).
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.